Target intelligence / Profile preview

Plasmodium digestive vacuole proteins (DV proteins)

Target
DV proteins
Molecular classification
Enzyme, Protease, Transporter, Other
01

Overview

The Plasmodium digestive vacuole (DV) is a specialized acidic organelle essential for the survival of the malaria parasite during its intraerythrocytic stage (Francis, S. E., et al. 1997. Annu Rev Microbiol). Within the DV, the parasite degrades host hemoglobin to obtain essential amino acids, a process mediated by a suite of enzymes including plasmepsins (aspartic proteases) and falcipains (cysteine proteases) (Wunderlich, J., et al. 2012. Int J Med Microbiol). A critical byproduct of this degradation is free heme (ferriprotoporphyrin IX), which is toxic to the parasite; to survive, the parasite detoxifies heme by sequestering it into an insoluble crystalline form called hemozoin (Egan, T. J. 2008. Drug Des Devel Ther). This pathway is the primary target for many classic antimalarial drugs, such as chloroquine and quinine, which interfere with hemozoin formation, leading to the accumulation of toxic heme and parasite death (Tilley, L., et al. 2016. Dalton Trans). Additionally, artemisinin-based compounds are activated by heme within the DV to produce free radicals that damage parasite membranes and proteins (Tilley, L., et al. 2016. Dalton Trans). The DV also contains transporters like PfCRT and PfMDR1, which are central to the development of drug resistance by modulating drug concentrations within the organelle (Wunderlich, J., et al. 2012. Int J Med Microbiol).

Other names
Heme detoxification pathwayHemoglobin degradation pathwayMalarial digestive vacuole enzymesHemozoin formation pathway
02

Mechanism of action

Inhibition of heme biocrystallization into hemozoin, leading to toxic heme accumulation; inhibition of hemoglobin-degrading proteases (plasmepsins and falcipains); and heme-mediated activation of endoperoxides to generate lethal free radicals.

03

Biological functions

Hemoglobin catabolismHeme detoxificationNutrient acquisitionIon homeostasisOther
04

Disease associations

Infection
05

Safety considerations

Emergence of drug resistance (e.g., PfCRT mutations)QT interval prolongationNeurotoxicity
06

Interacting drugs

Chloroquine

7 more in the full profile.

07

Biomarkers

HemozoinPlasmodium falciparum histidine-rich protein 2 (PfHRP2)Plasmodium lactate dehydrogenase (pLDH)

Beyond the preview

Go deeper on Plasmodium digestive vacuole proteins (DV proteins).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Plasmodium digestive vacuole proteins (DV proteins).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call